Preoperative Predictors of Early Mortality Risk in People with Osteosarcoma of the Extremities Treated with Standard Therapy

References

• Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320–325. doi:10.1093/annonc/mdq276
   PubMed Web of Science ®Google Scholar
• Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–3035. doi:10.1200/JCO.2014.59.4895
   PubMed Web of Science ®Google Scholar
• Zhong J, Hu Y, Si L, et al. Clarifying prognostic factors of small cell osteosarcoma: a pooled analysis of 20 cases and the literature. J Bone Oncol. 2020;24:100305. doi:10.1016/j.jbo.2020.100305
   PubMed Web of Science ®Google Scholar
• Roberts RD, Lizardo MM, Reed DR, et al. Provocative questions in osteosarcoma basic and translational biology: a report from the Children’s Oncology Group. Cancer. 2019;125(20):3514–3525. doi:10.1002/cncr.32351
   PubMed Web of Science ®Google Scholar
• Ji X, Shan L, Shen P, He M. Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression. Cell Death Dis. 2020;11(1):18. doi:10.1038/s41419-019-2204-y
   PubMed Web of Science ®Google Scholar
• Sheng K, Li Y. LncRNA TUG1 promotes the development of osteosarcoma through RUNX2. Exp Ther Med. 2019;18(4):3002–3008. doi:10.3892/etm.2019.7880
   PubMed Web of Science ®Google Scholar
• Zhou B, Li L, Li Y, Sun H, Zeng C. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother. 2018;106:850–857. doi:10.1016/j.biopha.2018.07.003
   PubMed Web of Science ®Google Scholar
• Shen H, Deng G, Chen Q, Qian J. The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database. BMC Cancer. 2021;21(1):825. doi:10.1186/s12885-021-08490-4
   PubMed Web of Science ®Google Scholar
• Zhu Y, Fang X, Wang L, Zhang T, Yu D. A predictive nomogram for early death of metastatic gastric cancer: a retrospective study in the SEER database and China. J Cancer. 2020;11(18):5527–5535. doi:10.7150/jca.46563
   PubMed Web of Science ®Google Scholar
• Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4(3):250–255. doi:10.1007/s11912-002-0023-1
   PubMedGoogle Scholar
• Li LQ, Bai ZH, Zhang LH, et al. Meta-analysis of hematological biomarkers as reliable indicators of soft tissue sarcoma prognosis. Front Oncol. 2020;10:30. doi:10.3389/fonc.2020.00030
   PubMed Web of Science ®Google Scholar
• Liu B, Huang Y, Sun Y, et al. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep. 2016;6:39862. doi:10.1038/srep39862
   PubMed Web of Science ®Google Scholar
• Liang YJ, Mei XY, Zeng B, et al. Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma. BMC Cancer. 2021;21(1):122. doi:10.1186/s12885-021-07841-5
   PubMed Web of Science ®Google Scholar
• Wasserman JK, Nicholas G, Yaworski R, et al. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One. 2015;10(4):e0123890. doi:10.1371/journal.pone.0123890
   PubMed Web of Science ®Google Scholar
• Zhu Z, Wang X, Wang J, et al. Preoperative predictors of early death risk in bladder cancer patients treated with robot-assisted radical cystectomy. Cancer Med. 2019;8(7):3447–3452. doi:10.1002/cam4.2237
   PubMed Web of Science ®Google Scholar
• Zhao C, Li L, Guo X, et al. Preoperative predictors of early mortality risk in isocitrate dehydrogenase-wild-type glioblastoma patients treated with standard therapy. Cancer Manag Res. 2021;13:1159–1168. doi:10.2147/CMAR.S290053
   PubMed Web of Science ®Google Scholar
• Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. Eval Chemotherapeutic Agents. 1949;4:191–205.
   Google Scholar
• Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur j Cancer. 2019;109:36–50. doi:10.1016/j.ejca.2018.11.027
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790. doi:10.1200/JCO.2002.20.3.776
   PubMed Web of Science ®Google Scholar
• Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011–2018. doi:10.1200/JCO.2003.08.132
   PubMed Web of Science ®Google Scholar
• Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. doi:10.1186/s12916-020-01817-1
   PubMed Web of Science ®Google Scholar
• Daher S, Lawrence YR, Dudnik E, et al. Nivolumab in non-small cell lung cancer: real world long-term survival results and blood-based efficacy biomarkers. Front Oncol. 2021;11:625668. doi:10.3389/fonc.2021.625668
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261
   PubMed Web of Science ®Google Scholar
• De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10(15):4895–4900. doi:10.1158/1078-0432.CCR-03-0760
   PubMed Web of Science ®Google Scholar
• Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15(2):73–86. doi:10.1038/nri3789
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc3611
   PubMed Web of Science ®Google Scholar
• Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev. 2002;28(3):137–140. doi:10.1016/S0305-7372(02)00044-0
   PubMed Web of Science ®Google Scholar
• Bestari MB, Agustanti N. Obstructive jaundice due to pancreatic metastasis from non-small cell lung cancer. Acta Medica Indonesiana. 2013;45(3):216–219.
   PubMedGoogle Scholar
• Page MJ, Thomson GJA, Nunes JM, et al. Serum amyloid A binds to fibrin (ogen), promoting fibrin amyloid formation. Sci Rep. 2019;9(1):3102. doi:10.1038/s41598-019-39056-x
   PubMed Web of Science ®Google Scholar
• Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100(5):859–865. doi:10.1111/j.1349-7006.2009.01115.x
   PubMed Web of Science ®Google Scholar